[Anticoagulation in thrombolytic therapy: importance and future perspectives].
The present overview describes the mode of action of direct and indirect anticoagulants. Furthermore it presents well-accepted and potential indications for the different anticoagulants as concomitant treatment during thrombolysis of deep vein thrombosis, pulmonary embolism and myocardial infarction. The new antithrombotics dermatansulfate, hirudine, synthetic peptide thrombin inhibitors, activated protein C, inhibitors of glycoprotein IIb/IIIa are reviewed. Many small and large studies on the thrombolytic treatment of myocardial infarction demonstrate the benefit of simultaneous application of heparins.
Harenberg
J
J
I. Medizinische Klinik, Fakultät Klinische Medizin Mannheim der Universität Heidelberg.
Heene
D L
DL
D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D005343:Fibrinolytic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D005544:Forecasting; D006801:Humans; D009203:Myocardial Infarction / Q000097:blood / Q000188:drug therapy; D011655:Pulmonary Embolism / Q000097:blood / Q000188:drug therapy; D015912:Thrombolytic Therapy / Q000639:trends*; D013924:Thrombophlebitis / Q000097:blood / Q000188:drug therapy; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy*
D000925:Anticoagulants; D005343:Fibrinolytic Agents
Antikoagulation bei Thrombolysetherapie: Bedeutung und Zukunftsperspektiven.